ProCE Banner Activity

New Targeted Therapies and Emerging Data in Urothelial Carcinoma

Slideset Download
Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.

Released: February 26, 2021

Expiration: February 25, 2022

No longer available for credit.

Share

Faculty

Petros Grivas

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Immunomedics

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington